NCT Number: NCT00444340
An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis
This study is an extension trial of 0881A3-312-EU and is designed to provide information on the safety and efficacy of etanercept in patients with ankylosing spondylitis for up to 3 additional years.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Completed study 0881A3-312-EU
- Agreeable to utilize medically acceptable form of contraception
- Able to reconstitute and self-inject or have a designee
Exclusion criteria
- Withdrawn from study 0881A3-312-EU
- Abnormal hematology or chemistry profiles
- Clinically relevant medical conditions including: congestive heart failure, multiple sclerosis or other central demyelinating diseases, blood dyscrasias, cancer or serious infection
Treatment and study plan
Primary outcomes
-
To evaluate the long-term safety of etanercept in adults with ankylosing spondylitis who have completed study 0881A3-312-EU.
Secondary outcomes
-
To assess the long-term clinical efficacy of etanercept in these study subjects.
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis
Important dates
- Study start
- 2004
- Study completion
- 2007
- First posted
- Mar 7, 2007
- Registry last updated
- Dec 7, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
NCT03928743
Ankylosing Spondylitis, Ankylosis
Mesa, Arizona, United States
View Trial DetailsExtension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)
NCT05861128
Ankylosing Spondylitis, Ankylosis
Shanghai, Shanghai Municipality, China
View Trial DetailsEfficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)
NCT05861102
Ankylosing Spondylitis, Ankylosis
Shanghai, Shanghai Municipality, China
View Trial DetailsLacticaseibacillus Rhamnosus GG Supplementation in Active Ankylosing Spondylitis
NCT07834788
Ankylosing Spondylitis, Ankylosis
Adana, Balcalı, Turkey (Türkiye)
View Trial Details